Approach to drug-resistant cytomegalovirus in transplant recipients

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose of review The purpose of this study is to provide updated information on diagnosis of cytomegalovirus (CMV) drug resistance, treatments for drug-resistant infection and potential uses of experimental antiviral compounds. Recent findings For established CMV antivirals, uncommon viral UL97 kinase and UL54 DNA polymerase drug resistance mutations are sporadically described that expand an extensive existing database. Some novel mutations reported from treated patients have no drug-resistant phenotype and may be genotyping artefacts. Next-generation sequencing technology may enable earlier detection of emerging resistance mutations in treated patients. Management options for drug-resistant infection include optimization of host defenses, antiviral dose escalation, substitutions or combinations of standard or experimental antivirals. Maribavir and letermovir have antiviral targets distinct from the classic DNA polymerase. UL97 mutations elicited by ganciclovir and maribavir are different, although a single p-loop mutation can confer significant cross-resistance. High-grade resistance mutations in the UL56 terminase gene are readily selected in vitro under letermovir and await clinical correlation. Summary Technical advancements can enhance the accurate and timely genotypic detection of drug resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug combinations, but unresolved issues exist with regard to their therapeutic potential for drug-resistant CMV and their genetic barriers to resistance.

Original languageEnglish (US)
Pages (from-to)293-299
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Volume28
Issue number4
DOIs
StatePublished - Aug 25 2015

Fingerprint

Cytomegalovirus
Antiviral Agents
Mutation
Drug Resistance
Pharmaceutical Preparations
DNA-Directed DNA Polymerase
Ganciclovir
Drug Combinations
Infection
Artifacts
Transplant Recipients
Phosphotransferases
Clinical Trials
Databases
Technology
Phenotype
Therapeutics
Genes

Keywords

  • antiviral drug resistance
  • brincidofovir
  • cytomegalovirus
  • letermovir
  • maribavir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Approach to drug-resistant cytomegalovirus in transplant recipients. / Chou, Sunwen.

In: Current Opinion in Infectious Diseases, Vol. 28, No. 4, 25.08.2015, p. 293-299.

Research output: Contribution to journalArticle

@article{7cbb045d714842909ddf8064b0eee5f7,
title = "Approach to drug-resistant cytomegalovirus in transplant recipients",
abstract = "Purpose of review The purpose of this study is to provide updated information on diagnosis of cytomegalovirus (CMV) drug resistance, treatments for drug-resistant infection and potential uses of experimental antiviral compounds. Recent findings For established CMV antivirals, uncommon viral UL97 kinase and UL54 DNA polymerase drug resistance mutations are sporadically described that expand an extensive existing database. Some novel mutations reported from treated patients have no drug-resistant phenotype and may be genotyping artefacts. Next-generation sequencing technology may enable earlier detection of emerging resistance mutations in treated patients. Management options for drug-resistant infection include optimization of host defenses, antiviral dose escalation, substitutions or combinations of standard or experimental antivirals. Maribavir and letermovir have antiviral targets distinct from the classic DNA polymerase. UL97 mutations elicited by ganciclovir and maribavir are different, although a single p-loop mutation can confer significant cross-resistance. High-grade resistance mutations in the UL56 terminase gene are readily selected in vitro under letermovir and await clinical correlation. Summary Technical advancements can enhance the accurate and timely genotypic detection of drug resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug combinations, but unresolved issues exist with regard to their therapeutic potential for drug-resistant CMV and their genetic barriers to resistance.",
keywords = "antiviral drug resistance, brincidofovir, cytomegalovirus, letermovir, maribavir",
author = "Sunwen Chou",
year = "2015",
month = "8",
day = "25",
doi = "10.1097/QCO.0000000000000170",
language = "English (US)",
volume = "28",
pages = "293--299",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Approach to drug-resistant cytomegalovirus in transplant recipients

AU - Chou, Sunwen

PY - 2015/8/25

Y1 - 2015/8/25

N2 - Purpose of review The purpose of this study is to provide updated information on diagnosis of cytomegalovirus (CMV) drug resistance, treatments for drug-resistant infection and potential uses of experimental antiviral compounds. Recent findings For established CMV antivirals, uncommon viral UL97 kinase and UL54 DNA polymerase drug resistance mutations are sporadically described that expand an extensive existing database. Some novel mutations reported from treated patients have no drug-resistant phenotype and may be genotyping artefacts. Next-generation sequencing technology may enable earlier detection of emerging resistance mutations in treated patients. Management options for drug-resistant infection include optimization of host defenses, antiviral dose escalation, substitutions or combinations of standard or experimental antivirals. Maribavir and letermovir have antiviral targets distinct from the classic DNA polymerase. UL97 mutations elicited by ganciclovir and maribavir are different, although a single p-loop mutation can confer significant cross-resistance. High-grade resistance mutations in the UL56 terminase gene are readily selected in vitro under letermovir and await clinical correlation. Summary Technical advancements can enhance the accurate and timely genotypic detection of drug resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug combinations, but unresolved issues exist with regard to their therapeutic potential for drug-resistant CMV and their genetic barriers to resistance.

AB - Purpose of review The purpose of this study is to provide updated information on diagnosis of cytomegalovirus (CMV) drug resistance, treatments for drug-resistant infection and potential uses of experimental antiviral compounds. Recent findings For established CMV antivirals, uncommon viral UL97 kinase and UL54 DNA polymerase drug resistance mutations are sporadically described that expand an extensive existing database. Some novel mutations reported from treated patients have no drug-resistant phenotype and may be genotyping artefacts. Next-generation sequencing technology may enable earlier detection of emerging resistance mutations in treated patients. Management options for drug-resistant infection include optimization of host defenses, antiviral dose escalation, substitutions or combinations of standard or experimental antivirals. Maribavir and letermovir have antiviral targets distinct from the classic DNA polymerase. UL97 mutations elicited by ganciclovir and maribavir are different, although a single p-loop mutation can confer significant cross-resistance. High-grade resistance mutations in the UL56 terminase gene are readily selected in vitro under letermovir and await clinical correlation. Summary Technical advancements can enhance the accurate and timely genotypic detection of drug resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug combinations, but unresolved issues exist with regard to their therapeutic potential for drug-resistant CMV and their genetic barriers to resistance.

KW - antiviral drug resistance

KW - brincidofovir

KW - cytomegalovirus

KW - letermovir

KW - maribavir

UR - http://www.scopus.com/inward/record.url?scp=84937960754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937960754&partnerID=8YFLogxK

U2 - 10.1097/QCO.0000000000000170

DO - 10.1097/QCO.0000000000000170

M3 - Article

VL - 28

SP - 293

EP - 299

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 4

ER -